Hematopoietic Stem Cells from Human Term Placenta
Hematopoietic Stem Cells from Human Term Placenta
批准号:
8290455
负责人:
Fernando Viteri
金额:
$24.04万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2013-06-30
关键词:
BirthBlindedBlood BanksBone Marrow TransplantationCell CountCellsChildCollaborationsCollectionCryopreservationFred Hutchinson Cancer Research CenterFundingFutureGuidelinesHarvestHematologyHematopoieticHematopoietic stem cellsHumanLeadLifeNCI Center for Cancer ResearchNational Institute of Diabetes and Digestive and Kidney DiseasesPatientsPediatric HospitalsPhasePlacentaPreparationProtocols documentationPublicationsPublishingReadingResearchResearch InstituteResearch PersonnelResourcesScientistSmall Business Innovation Research GrantSourceStagingStem cellsTechniquesTechnologyTransplantationUmbilical Cord BloodUmbilical Cord Blood Transplantationcommercializationexperienceimprovednew technologynovelstem
中文摘要
描述(由申请人提供):不幸的是,只有一小部分需要移植造血干细胞的患者能够从这种挽救生命的治疗中受益。成功的移植需要足够数量的免疫匹配的干细胞,这是一种非常有限的资源。婴儿出生后采集的脐带血是一种有效的造血干细胞和祖细胞(HSPC)来源。然而,虽然脐带血用于移植的利用正在扩大,但每个单位的细胞含量严重限制了其应用。此外,超过一半的脐带血没有储存在公共脐带血库中,因为干细胞计数不能保证储存以备将来使用。PlaSalus的目标是通过使用人类胎盘这个术语来定义克服这些限制的方案。我们建议利用新技术开发胎盘作为HSPC的新来源,以增加和大大改善目前可用的骨髓移植细胞资源。我们的目标是1。定义收集和准备协议,兼容不同的孩子出生设置;2 .制定冷冻保存方案,使胎盘能够长期保存,并与当前脐带血保存方法兼容;定义干细胞采集方案,与人类移植环境的使用兼容。PlaSalus将与奥克兰儿童医院研究所的专家以及NIDDK资助的西雅图癌症研究中心核心血液学卓越中心密切合作,为这一重要资源的商业化奠定基础。
英文摘要
DESCRIPTION (provided by applicant): Unfortunately only a fraction of patients in need of transplantation with hematopoietic stem cells can benefit from this life saving treatment. Successful transplantation requires sufficient numbers of immunologically-matched stem cells, a highly limited resource. Cord blood collected after the birth of the baby, is a validated source of hematopoietic stem and progenitor cells (HSPC). However, while the utilization of umbilical cord blood for transplantation is expanding, the cellular content of each unit severely limits its application. Moreover, more than half of the cord blood units collected are not stored in public cord blood banks, as the stem cell count does not warrant storage for future use. PlaSalus aims to define protocols that will overcome these limitations, by the use of human term placenta. Using novel technology we propose to develop the placenta as novel source for HSPC to augment and drastically improve the current available cell resources for bone marrow transplant. We aim to 1. Define collection and preparation protocols, compatible with various child birth settings, 2. Define cryopreservation protocols to allow long-term storage of placenta, compatible with current cord blood storage efforts, and 3. Define stem cell harvesting protocols, compatible with use in human transplant settings. PlaSalus will closely collaborate with experts from Children's Hospital Oakland Research Institute, and the Cancer Research Centers NIDDK funded Core Center of Excellence in Hematology in Seattle, to set the stage for the commercialization of this important resource.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Stromal Stem Cells of Human Placenta for the Treatment of Acute Lung Injury
-
批准号:8518446
-
项目类别:
-
资助金额:$18.24万
-
财政年份:2012
-
负责人:Fernando Viteri
-
依托单位:
Stromal Stem Cells of Human Placenta for the Treatment of Acute Lung Injury
-
批准号:8251414
-
项目类别:
-
资助金额:$17.87万
-
财政年份:2012
-
负责人:Fernando Viteri
-
依托单位:
Hematopoietic Stem Cells from Human Term Placenta
-
批准号:8109465
-
项目类别:
-
资助金额:$24.93万
-
财政年份:2011
-
负责人:Fernando Viteri
-
依托单位:
海外基金